Get the Stockscreener App
0.289
5.82%
0.0159
After Hours:
.28
-0.009
-3.11%
IGC Pharma Inc stock is traded at $0.289, with a volume of 138.74K.
It is up +5.82% in the last 24 hours and up +7.08% over the past month.
India Globalization Capital, Inc. engages in the development and commercialization of cannabis-based therapies to treat Alzheimer's, pain, nausea, eating disorders, several end points of Parkinson's, and epilepsy in humans, dogs, and cats. The company operates through two segments, Legacy Infrastructure and Medical Cannabis Based Alternative Therapies. The Legacy Infrastructure segment trades in infrastructure commodities, such as steel and iron ore; and rents heavy equipment. The Medical Cannabis Based Alternative Therapies segment offers IGC-501 for indications of neuropathic pain; Serosapse for indications of Parkinson's and other central nervous system disorders; Caesafin for seizures in cats and dogs; and Natrinol for indications of cancer and AIDS induced nausea and vomiting, as well as Hyalolex for Alzheimer's patients. The company was founded in 2005 and is based in Bethesda, Maryland.
See More
Previous Close:
$0.2731
Open:
$0.2705
24h Volume:
138.74K
Relative Volume:
0.25
Market Cap:
$27.47M
Revenue:
$1.22M
Net Income/Loss:
$-14.15M
P/E Ratio:
-1.1115
EPS:
-0.26
Net Cash Flow:
$-6.55M
1W Performance:
+3.62%
1M Performance:
+7.08%
6M Performance:
-38.51%
1Y Performance:
+3.96%
1-Day Range:
$0.2702
$0.289
1-Week Range:
$0.265
$0.305
52-Week Range:
$0.242
$0.4985
IGC Pharma Inc Stock (IGC) Company Profile
Name
IGC Pharma Inc
Sector
Industry
Phone
301-983-0998
Address
4336 Montgomery Avenue, Bethesda, MD
Compare IGC vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IGC
IGC Pharma Inc
|
0.289 | 25.95M | 1.22M | -14.15M | -6.55M | -0.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.27 | 123.47B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
766.66 | 83.60B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
748.72 | 46.83B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
318.65 | 43.11B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
297.04 | 34.79B | 4.98B | 69.60M | 525.67M | 0.5198 |
IGC Pharma Inc Stock (IGC) Latest News
IGC Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
IGC Should I Buy - Intellectia AI
IGC Pharma Files Utility Patent Applications Covering AI-Based Data Harmonization Architecture Suppo - PharmiWeb.com
Inside IGC Pharma’s AI push to clean up Alzheimer’s data - Stock Titan
IGC PE Ratio & Valuation, Is IGC Overvalued - Intellectia AI
FOMO Trade: What is the Moat Score of IGC Pharma IncBond Market & Verified Momentum Stock Ideas - baoquankhu1.vn
Trend Report: What is the Moat Score of IGC Pharma IncJuly 2025 Recap & Stepwise Trade Signal Implementation - baoquankhu1.vn
IGC Pharma Notes Updated Research Coverage from Ascendiant Capital Markets - The Globe and Mail
Aug Final Week: Is IGC Pharma Inc a cyclical or defensive stockWatch List & Real-Time Sentiment Analysis - baoquankhu1.vn
IGC Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
IGC Pharma expands Phase 2 CALMA trial with new clinical site - Yahoo Finance
Analyst lifts IGC Pharma price target to $5 in new research note - Stock Titan
IGC Enhances Alzheimer's Trial with New Clinical Research Collab - GuruFocus
IGC Pharma Adds Visionary Investigators Network as Clinical Site to Phase 2 CALMA Trial - Weatherford Democrat
Miami neurology network joins Alzheimer’s agitation drug trial - Stock Titan
Will IGC Pharma Inc. stock go up in YEARDay Trade & Daily Momentum Trading Reports - mfd.ru
Trend Review: Will IGC Pharma Inc benefit from green energy policiesJuly 2025 PreEarnings & Weekly Watchlist of Top Performers - baoquankhu1.vn
IGC: CALMA trial nears completion and MINT-AD AI platform set for beta launch amid favorable regulations - TradingView
IGC: Alzheimer's drug trial nears completion as AI dementia tool readies for beta launch - TradingView
Is IGC Pharma Inc. stock a buy before product launchesJuly 2025 Movers & Long Hold Capital Preservation Tips - mfd.ru
IGC Pharma Secures North American Composition Protection for IGC-AD1 as Phase 2 CALMA Enrollment Advances - GuruFocus
Low-dose THC Alzheimer’s drug from IGC wins key North America patent - Stock Titan
IGC Pharma to Participate in Fireside Chat With Ascendiant Capital Markets - Finviz
Is IGC Pharma Inc. likely to announce a buybackJuly 2025 Market Mood & Daily Entry Point Alerts - mfd.ru
Inside an Alzheimer’s trial: IGC Pharma talks new drug and AI treatment push - Stock Titan
Aug Catalysts: Should I trade or invest in IGC Pharma IncJuly 2025 Intraday Action & Stepwise Swing Trade Plans - baoquankhu1.vn
Why IGC Pharma Inc. (IGS1) stock could rally stronglyJuly 2025 Breakouts & Accurate Entry and Exit Point Alerts - mfd.ru
IGC Pharma Announces Equity Research Update by Alliance Global Partners - BioSpace
IGC Pharma Announces Equity Research Update by Alliance Global P - GuruFocus
IGC Pharma Expands Phase 2 CALMA Trial into Colombia's Premier Alzheimer's Research Center - BioSpace
IGC Pharma Expands Phase 2 CALMA Trial into Colombia's Premier A - GuruFocus
IGC Pharma Expands Key Alzheimer's Trial into Colombia - GuruFocus
Colombia’s unique inherited Alzheimer’s community joins IGC drug trial - Stock Titan
Trade Report: Will IGC Pharma Inc benefit from green energy policiesWall Street Watch & Real-Time Buy Signal Notifications - baoquankhu1.vn
Trend Recap: Can IGC Pharma Inc ride the EV wave2025 Support & Resistance & Daily Profit Maximizing Tips - baoquankhu1.vn
Treasury Yields: Is IGC Pharma Inc in a bullish channelJuly 2025 EndofMonth & Low Drawdown Investment Ideas - baoquankhu1.vn
Retail Trends: Can SUUN sustain earnings growth2025 Macro Impact & Weekly High Return Stock Forecasts - baoquankhu1.vn
Market Pulse: How volatile is ProShares Trust ProShares Short High Yield stockPortfolio Profit Report & Expert-Curated Trade Recommendations - baoquankhu1.vn
Is IGC Pharma Inc. (IGS1) stock undervalued historicallyJuly 2025 Price Swings & AI Driven Price Forecasts - mfd.ru
IGC Pharma Reaches 70% Enrollment in Phase 2 CALMA Trial Evaluating IGC-AD1 for Alzheimer's Agitation - Weatherford Democrat
Forecast Cut: Is IGC Pharma Inc a cyclical or defensive stockJuly 2025 Outlook & High Return Stock Watch Alerts - baoquankhu1.vn
Setup Watch: Is IGC Pharma Inc a momentum stockJuly 2025 Recap & Real-Time Volume Spike Alerts - baoquankhu1.vn
Aug Breakouts: How does IGC Pharma Inc perform in inflationary periods2025 Winners & Losers & Free Expert Verified Stock Movement Alerts - baoquankhu1.vn
Aug Volume: Should I buy SONY stock nowEarnings Growth Summary & Verified Momentum Stock Ideas - baoquankhu1.vn
IGC Pharma announces registered direct equity offering financing - MSN
IGC Pharma Expands Phase 2 CALMA Trial With New Clinical Trial Site at Integrative Clinical Trials in New York - 富途牛牛
IGC Pharma Expands Phase 2 CALMA Trial with New Clinical Trial Site at Integrative Clinical Trials in New York - Finviz
IGC Pharma Expands Phase 2 CALMA Trial with New Clinical Trial S - GuruFocus
IGC Expands Alzheimer's Clinical Trial with New Site in Brooklyn - GuruFocus
IGC Pharma Inc Stock (IGC) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.71%
0.02%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):